CSIMarket
 


X4 Pharmaceuticals Inc  (XFOR)
Other Ticker:  
 

X4 Pharmaceuticals Inc's Long Term Debt to Equity

XFOR's quarterly Long Term Debt to Equity and Long Term Debt, Equity growth


In the first quarter 2024 X4 Pharmaceuticals Inc did not have Long Term Debt.

Within Biotechnology & Pharmaceuticals industry X4 Pharmaceuticals Inc achieved the lowest Long Term Debt to Equity in the first quarter 2024. While total ranking remained the same in the first quarter 2024 compared to the previous quarter at no. .

Explain Long Term Debt to Equity Ratio?
How much Long Term Debt XFOR´s has?
What is the structure of XFOR´s Equity?


XFOR Long Term Debt to Equity (Mar 31 2024)
I. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
III. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity Change -98.6 % 9.29 % 124.57 % 3.95 % 14.96 %
Y / Y Long Term Debt Change - - - - -
Long Term Debt to Equity MRQ - - - - -
XFOR's Total Ranking # # # # #
Seq. Equity Change -98.47 % 0.09 % 30.69 % -30.22 % 19.73 %
Seq. Long Term Debt Change - - - - -



Long Term Debt to Equity first quarter 2024 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall Market #


Long Term Debt to Equity Statistics
High Average Low
0 0 0
 




Financial Statements
X4 Pharmaceuticals Inc's Equity $ 1 Millions Visit XFOR's Balance sheet
X4 Pharmaceuticals Inc's Long Term Debt $ 0 Millions Visit XFOR's Balance sheet
Source of XFOR's Sales Visit XFOR's Sales by Geography


Cumulative X4 Pharmaceuticals Inc's Long Term Debt to Equity

XFOR's Long Term Debt to Equity for the trailling 12 Months

XFOR Long Term Debt to Equity

(Mar 31 2024)
I. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
III. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity TTM Growth -98.6 % 9.29 % 124.57 % 3.95 % 14.96 %
Y / Y Long Term Debt TTM Growth - - - - -
Long Term Debt to Equity TTM - - - - -
Total Ranking TTM
Seq. Equity TTM Growth -98.47 % 0.09 % 30.69 % -30.22 % 19.73 %
Seq. Long Term Debt TTM Growth - - - - -


On the trailing twelve months basis During the twelve months ending I Quarter 2024 X4 Pharmaceuticals Inc did not have Long Term Debt .
Long Term Debt to Equity is the average cumulative value over the last four quarters.

Among companies in the Biotechnology & Pharmaceuticals industry XFOR recorded the lowest Long Term Debt to Equity. While total ranking remained unchanged compared to previous 12 month period at no. 0.

Explain Long Term Debt to Equity Ratio?
How much Long Term Debt XFOR´s has?
What is the structure of XFOR´s Equity?

TTM Long Term Debt to Equity Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Within the Market #


trailing twelve months Long Term Debt to Equity Statistics
High Average Low
0 0 0
 




Companies with similar Long Term Debt to Equity in the quarter ending Mar 31 2024, within Biotechnology & Pharmaceuticals Industry Long Term Debt to EquityMar 31 2024 MRQ Long Term DebtMar 31 2024 MRQ Equity

Date modified: 2024-05-08T15:34:55+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com